Omega Point · Hypothesis

Replacing small, distributed support-cell patches in the thymus is enough to slow aging

The hypothesis says replacing thymic mesenchymal organizer microdomains—small support-cell patches—with young, compatible cells can preserve function and improve survival. Distributed replacement must outperform the same cell number in one depot and protect nonimmune functions without peripheral matrix replacement.

Void gapCandidate set selectionMinimum Replacement Set, Quantity, Distribution, and Recurrence Determination1 rival hypothesespublished 2026-09-20

014 stages from the goal to this hypothesis

The logic

The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the explanation proposed here. Every step below says what it rests on and what carries it.

The descent, in plain words

Slowing aging might require replacing only a small part of the body, but the unresolved question is which part would be enough. The unexpected move is to nominate scattered support-cell patches in the thymus, the organ where T cells mature for immune defense, while retaining other organs and their surrounding structural material. This is a pipeline-generated proposal, not a measured result: it nominates 10% replacement at ages 60, 70 and 80 and predicts that placement matters as much as cell number.

The proposed mechanism, link by link

Young replacement support-cell patches supply FGF7 and FGF10 at selected positions across both halves of the thymus.
The signals spread and are removed locally, making patch spacing determine which retained epithelial territories receive concentrations within the proposed functional bounds.
Adequate local signaling is predicted to restore the organization and support provided by retained thymic epithelial cells.
The restored environment is predicted to increase production of naive T cells, immune cells that have not yet encountered their matching target.
Renewed immune protection is predicted to prevent enough disease elsewhere to preserve functions beyond immunity and improve survival without replacing other organs or their extracellular matrix.

A picture for it

Several small sprinklers spread across a garden can reach beds that one sprinkler delivering the same total water leaves dry. The proposal treats the placement of signal-producing cell patches as similarly important to the total number of cells.

Where the picture breaks: Living cells can change their signal production and response, and the proposal requires concentrations within both lower and upper bounds. The picture cannot establish those bounds, the required number of cells, or whether local repair would extend life.

Master questionstep 01 of 04
The target is the smallest amount of tissue replacement that would slow aging and extend lifespan, including exactly which cells or structures between cells need changing.
Rests on: The goal itself requires identifying both what must be replaced and how little replacement can achieve the desired outcomes.
Stated in the chain
Goal pillarstep 02 of 04
A minimum replacement plan must specify its targets, quantity, distribution and treatment schedule.
Rests on: The master question explicitly calls for the smallest amount and exact locations; treating repeat treatments as part of that minimum introduces a scheduling dimension.
Assumption
The stage assumes that treatment recurrence must be evaluated as part of the minimum plan; the master question does not explicitly specify repeated replacement.
Gap questionstep 03 of 04
Removing targets from a candidate replacement plan and comparing the smaller plans with otherwise matched care involving no replacement would identify which tissues, cells and structures between cells must change and which can remain.
Rests on: The preceding stage calls for a minimum set and amount, with specified distribution and recurrence; comparisons against smaller sets make that minimum claim testable.
Stated in the chain
Hypothesisstep 04 of 04
Small thymic mesenchymal organizer microdomains, local patches of connective-tissue support cells in the thymus, are proposed as the entire necessary replacement set. They contain cells producing fibroblast growth factors 7 and 10, called FGF7 and FGF10, which are signals involved in maintaining the thymus's supporting cells. The nominated treatment replaces 10% of the starting support-cell population with functionally young, compatible cells across both halves of the thymus at ages 60, 70 and 80. It retains thymic epithelial cells, the cells forming the environment for T-cell development; hematopoietic stem cells, which generate blood and immune cells; immune cells carrying memories of previous encounters; and all other organs and their extracellular matrix, the material surrounding and supporting cells. The proposal predicts that 5% replacement or the same 10% collected in one site leaves territories without enough support. It further predicts that renewed immune protection would prevent enough later disease to slow aging and improve survival.S8
Rests on: The preceding stage supplies the smaller-set comparison, while the endpoint supplies a borrowed model in which signal production, spread and removal determine patch spacing. Biology Direct (2023), S8, describes these mouse support cells and their laboratory effects and discusses FGF7/FGF10 signaling to thymic epithelial cells; it does not establish replacement, the nominated dose or placement, or benefits for aging.
Supported by literature

What is carried, and what is not. The screened sources support parts of the biological background: Biology Direct (2023), S8, discusses support-cell signals but does not test replacement, while Frontiers in Immunology (2022), S1, reports accelerated T-cell regeneration in aged mice after supplying immature T cells under a conditioning regimen, not the nominated support-cell treatment. No supplied source establishes the full sequence from distributed replacement through preserved functions beyond immunity to longer survival, or validates the proposed percentages and treatment ages.S8 S1

Where the reasoning is carried by something unstated · 1

Goal pillar. The stage assumes that treatment recurrence must be evaluated as part of the minimum plan; the master question does not explicitly specify repeated replacement.

How a result here could mislead · 3

Better results from distributed cells than from a single collection could reflect differences in cell survival or signal production, rather than the claimed advantage of spatial coverage at an equal effective cell dose. What closes it: The comparison requires measurements of surviving introduced cells, their locations, signal production and concentrations across retained epithelial territories. Signal spread, removal and functional concentration bounds must be measured independently of the outcomes used to judge the model; equal introduced-cell counts alone do not establish equal effective doses.
A benefit after introducing young cells could be credited to replacing old cells even if adding cells or supplying their signals without replacement would produce the same benefit. What closes it: The test must document host-cell removal and replacement and compare it with cell addition, matched delivery of soluble signals, other feasible interventions without replacement, and matched care without replacement. The supplied specification requires these distinctions but does not provide a complete procedure for implementing them.
Improved T-cell production or immune protection could be read as sufficient evidence of slower whole-body aging, leaving the competing explanation about damaged material around cells elsewhere unresolved. What closes it: Success requires predefined measures of functions beyond immunity and survival alongside immune outcomes; the supplied material does not enumerate those functional measures. Separating the rival also requires establishing whether replacement of cell-facing attachment structures in extracellular matrix outside the thymus remains necessary after the proposed thymic signal coverage has been restored.

What would make this wrong. The central sufficiency claim would fail if verified distributed replacement restored the intended signal coverage and immune function but did not preserve the required functions beyond immunity or improve survival. Continued necessity for extracellular-matrix replacement elsewhere would also contradict the proposed thymus-only set. Equal success with 5% replacement, omitted source patches or a single collection of cells would separately defeat the corresponding minimum-dose or spatial-necessity claims.

What it would change. If the proposal held, a small, spatially arranged support-cell set could be sufficient for the master goal, and minimum replacement would have to be defined by location and recurrence as well as cell count. Comparisons would need to show that smaller amounts and omitted patches lose the required benefits while feasible care without replacement does not achieve them. Even success in aged mice would not establish human lifespan benefit or the proposed treatment ages, and success within the nominated comparisons would not prove that no still-smaller or entirely different replacement set could work.

Sources read · 8

4 literature searches, 10 full texts; 10 source(s) read in full against this question. A bounded search is not evidence of absence.

S1Background

Thymus Reconstitution in Young and Aged Mice Is Facilitated by In Vitro-Generated Progenitor T Cells. · Frontiers in immunology · 2022

“In short, here we have improved upon the conditioning regimen and discovered that providing proT cells allows for the effective reconstitution of the aged mouse thymus with accelerated T cell regeneration.”

Does not settle: It does not test thymic mesenchymal organizer microdomain replacement, FGF7/FGF10-producing stromal cells, any percentage or spatial distribution of replacement, repeated treatment ages, human outcomes, or whether thymic repair slows aging across downstream domains.

S2Background

Restoration of Thymus Function with Bioengineered Thymus Organoids. · Current stem cell reports · 2016

“One of the major caveats is that TECs are isolated and injected into the thymus scaffold as single cells, resulting in loss of cell-cell contact and geometrical organization of TECs in the bioengineered thymus organoids.”

Does not settle: This source does not establish that replacing only thymic mesenchymal organizer microdomains, at 10% or any dose, slows aging. It does not report FGF7/FGF10-producing cells, bilateral spatial coverage, repeated treatment at ages 60/70/80, human intrathymic replacement, or outcomes across downstream aging domains. The described functional organoids used multiple stromal cell types plus bone marrow progenitors in preclinical mouse models.

S3Background

Tbata modulates thymic stromal cell proliferation and thymus function. · The Journal of experimental medicine · 2010

“The dominant phenotypic feature of Tbata deficiency is the improved thymus function observed in aged Tbata −/− mice compared with WT mice.”

Does not settle: It does not test replacement of thymic mesenchymal organizer microdomains, FGF7/FGF10-producing cells, any cell-replacement dose or distribution, repeated treatment, human aging, or downstream aging outcomes.

S4Background

Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution. · Proceedings of the National Academy of Sciences of the United States of America · 2016

“Genetic gain of FGF21 function in mice protects against age-related thymic involution with an increase in earliest thymocyte progenitors and cortical thymic epithelial cells.”

Does not settle: This source reports FGF21 gain/loss experiments in mice, not replacement of thymic mesenchymal organizer microdomains. It does not establish a 10% cell-replacement dose, bilateral spatial distribution, repeat treatment ages, FGF7/FGF10-producing cells, adequacy of retained epithelial and hematopoietic populations, or downstream prevention of pathology across Q0 domains.

S5Background

Age-related epithelial defects limit thymic function and regeneration. · 2024

“Here, we define age-associated changes to the thymic microenvironment in the involuting thymus that impairs function in two ways.”

Does not settle: This source does not test replacement of thymic mesenchymal organizer microdomains, any 10% or 5% replacement dose, spatial distribution across lobes, repeated treatment at specified ages, human outcomes, or whether thymic intervention slows aging across Q0 domains.

S8Partly answers it

Nitric oxide-dependent immunosuppressive function of thymus-derived mesenchymal stromal/stem cells. · Biology direct · 2023

“MCs produce fibroblast growth factor-7 (FGF-7), FGF-10, insulin-like growth factor-1 (IGF-1), IGF-2 and retinoic acid [ – ] to regulate the proliferation of TECs. Moreover, MCs are indispensable for the of maintenance of TECs and thymus regeneration [ , ].”

Does not settle: This mouse study describes thymic mesenchymal stromal-cell distribution and in vitro immunomodulatory properties; it does not test replacement of cells, a 10% dose, bilateral spatial deployment, repeated treatment at any age, effects on aging or downstream pathology, or sufficiency in humans.

S9Background

Recirculating regulatory T cells mediate thymic regeneration through amphiregulin following damage. · Immunity · 2025

“The adoptive transfer of these cells improved thymic regeneration in both young and aged mice after injury.”

Does not settle: This source does not test replacement of thymic mesenchymal FGF7/FGF10-producing cells, any 10% dose or spatial distribution model, repeated treatment at specified human ages, or whether thymic intervention slows aging across Q0 domains.

S10Background

Proteasome inhibition promotes Foxn1 expression in thymic epithelial cells and induces thymic regeneration in mice. · Cell death and differentiation · 2026

“The thymus gland is the primary organ for the generation and education of T cells. This process is highly dependent on the cross talk between developing thymocytes and the thymic stromal compartment, which consists of thymic epithelial cells (TECs), macrophages, endothelial cells, fibroblasts, and dendritic cells.”

Does not settle: It does not test replacement of mesenchymal organizer microdomains, FGF7/FGF10-producing cells, a 10% dose, spatial distribution, repeated treatment at specified ages, aging outcomes, or downstream pathology across Q0 domains.

02The unknown

The gap this hypothesis explains

Nothing is known here: the question has not been asked of this system.

Which body parts must be replaced to slow aging and extend life, and which can remain intact?

Original wording · exactly as the pipeline generated it

The gap question, as the engine wrote it

Which tissues, anatomical regions, cell populations, extracellular matrix components, or other intercellular structures require replacement, and which can remain intact, when target-subtraction experiments compare candidate sets against smaller rivals and matched zero-replacement care?

What this question is asking

The question asks how little of the body could be replaced while still slowing aging and extending life. Possible targets include whole tissues, particular locations within them, groups of cells, the supporting material outside cells, and other structures between cells. It asks which targets remain necessary when a proposed combination is compared with combinations that omit targets, combinations placed elsewhere, and otherwise comparable care that replaces nothing. Success would require keeping every specified aspect of function within limits of decline set beforehand and demonstrating additional survival caused by replacement over at least thirty years, while accounting for everyone enrolled. The question assumes that existing optimization work, evidence about immune boundaries, and outcome-measurement methods constrain this search, but that no experiment has established a sufficient combination or ruled out smaller alternatives.

What the terms mean

Replacement target: A body component selected for replacement, such as a tissue, a location within it, a group of cells, or material between cells. The input does not specify exactly what procedures count as replacement.
Tissue and anatomical region: A tissue is an organized collection of cells and associated material; an anatomical region is a location in the body. A proposed replacement could involve an entire tissue or only a particular part of it.
Cell population: A group of cells considered together because they share a location or selected characteristics. The label does not necessarily mean that all cells in the group behave identically.
Extracellular matrix: The supporting material outside cells. The question treats components of this material as possible replacement targets alongside the cells themselves.
Intercellular structures: Structures between cells. This is a broad category in the question, and the supplied material does not identify its specific proposed targets.
Target-subtraction experiment: A comparison that removes one or more targets from a proposed replacement combination and measures what changes. It tests whether the omitted replacement is needed under those conditions.
Necessary target and sufficient combination: A necessary target is one whose omission prevents the requirements from being met in the relevant comparison. A sufficient combination meets all requirements, but that alone does not show that each of its targets is necessary or that it is the smallest successful combination.
Matched zero-replacement care: Care that replaces nothing and is otherwise made comparable to the replacement condition. It provides the comparison needed to distinguish benefits of replacement from benefits associated with other care.
Prespecified decline threshold: A limit on acceptable worsening set before results are assessed. The question requires such limits for every protected aspect of function, but supplies neither the aspects nor their numerical limits.
Replacement-attributable survival: Additional survival caused by replacement itself. Living longer after replacement would not alone establish this, because other differences could account for the result.
Optimization: Choosing among alternatives to meet an objective while respecting constraints. Here it refers to selecting replacement targets, but the supplied sources do not describe the claimed prior optimization work.
Immune-boundary evidence: The input's label for evidence concerning immune defenses and biological boundaries. It does not specify which boundaries, mechanisms, or findings this label denotes.
Outcome-measurement methods: Ways of measuring and comparing what happens after an intervention. Here the relevant results include preserved function and survival, but the claimed prior methods are not supplied.
Human mesenchymal progenitor cells: Human precursor cells associated with the formation of connective and supporting tissues. They are the cell group named in S4's title; the supplied quotation does not specify their preparation or establish which body structures their replenishment would replace.
Primates: The animal group that includes humans, monkeys, and apes. S4's title places its work in primates, but the supplied material does not identify the study species.
Cell replenishment: Adding cells to restore or supplement a cell population. The supplied material does not establish that replenishment amounts to replacement of a defined tissue or structure.

What the question takes for granted

Premise could not be checked

Existing optimization, immune-boundary evidence, and outcome methods provide search constraints, but no experimentally established sufficient replacement set or target-subtraction evidence excludes smaller or differently placed rivals while retaining matched nonreplacement alternatives and all enrolled participants.

The assumption concerns methods for choosing replacement targets, evidence about how immune defenses interact with biological boundaries, and methods for measuring results. It claims these offer guidance but have not identified a combination that meets all requirements or shown that smaller or differently located combinations cannot do so. If established, this would locate the missing knowledge specifically in comparisons that determine which replacements are necessary.

S4 supplies only an abstract and says that the feasibility of replenishing the cells it discusses to counter aging remains poorly defined. S7 describes several structures involved in skin aging. Neither supplied source establishes the claimed contributions of the three bodies of prior work or supports a literature-wide conclusion that qualifying comparisons do not exist; the supplied reading is too limited to audit that conclusion.S4 S7

The same question asked without the part nothing read establishes:

Which replacement targets, if any, are necessary to preserve every specified function within preset decline limits and increase survival over at least thirty years, compared with smaller or differently located combinations and comparable care without replacement?
What do comparisons of replacement combinations, combinations with individual targets omitted, and care without replacement establish about the smallest combination that slows aging and extends life?

What turns on the answer

Every proposed target is necessary If the complete combination met the requirements but every tested smaller combination failed because a target was omitted, each omitted target would be necessary within those comparisons. This would support retaining the complete combination, although necessity would remain bounded by the alternatives actually tested.
Some targets can remain intact If a smaller combination met all requirements after particular targets were omitted, replacing those targets would not be necessary under the tested conditions. The supported replacement scope would shrink, with the omitted structures left intact.
A differently located combination succeeds If a combination acting at different body locations met the requirements, the original locations would not be the only route to the intended benefit. Establishing the least replacement would then depend on comparisons between those successful alternatives.
No tested combination meets the requirements If replacement failed to add survival over comparable care or allowed any specified function to decline beyond its limit, none of the tested combinations would qualify. That result would leave the required targets unidentified rather than establish that replacement can never work.

Why it matters

The proposed chain is that replacing selected body components would preserve function, and that preserving function would translate into longer survival. A combination that helps does not by itself establish that every component in it needed replacement. If removing a component leaves the benefit unchanged, the larger combination cannot establish that component's necessity. Conversely, omitting a necessary component could leave a source of decline unaddressed. Without comparable care that replaces nothing, a survival difference could not be assigned confidently to replacement rather than to other differences in care.

What is already established

RL-1 optimization, RL-2 immune-boundary evidence, and RL-3 outcome methods provide search constraints but no experimentally established sufficient set.

What would have to be true

Identify necessary targets while preserving every domain below prespecified decline thresholds and increasing replacement-attributable survival over at least thirty years.

What is missing

No target-subtraction evidence excludes smaller or differently placed rivals while retaining matched nonreplacement alternatives and all enrolled participants.

03The claim

The mechanism it proposes

The engine's own statement of the hypothesis, in full.

CROSS-DOMAIN TRANSFER — The minimal set consists only of thymic mesenchymal organizer microdomains containing FGF7/FGF10-producing stromal cells. Replace10%of the baseline intrathymic mesenchymal-cell population with functionally young, compatible cells, distributed among both thymic lobes at positions selected by a morphogen-threshold coverage model; repeat at ages 70 and 80 after the initial age-60 episode. Retain thymic epithelial cells, hematopoietic stem cells, mature immune-memory populations, all nonthymic organs and their ECM. The proposed sufficient set restores spatially patterned thymopoietic support using retained epithelial and hematopoietic populations; subsequent immune renewal prevents enough downstream pathology to satisfy all Q0 domains. Within the nominated grid,5%replacement cannot establish adequate signaling coverage, and the same10%concentrated in one depot leaves unsupported territories. Thus cell location, as well as the small specified cell set, determines minimality. The10%dose is an experimental hypothesis, not an evidence-based human requirement.

04The test

The prediction that would tell it apart

A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.

At identical introduced-cell number, correctly distributed organizer replacement restores epithelial spatial organization, naive T-cell production and immune protection, while a concentrated depot fails. The distributed set also preserves nonimmune functional domains and improves survival without replacing peripheral ECM. Halving the dose or deleting source patches that uniquely cover a territory destroys sufficiency. If only immune outcomes improve, the proposed set is insufficient for Q0. If peripheral ligand replacement remains necessary after organizer coverage is restored, IH_Q_L3_M_G1_1_01 gains support over this candidate.

Would tell it apart from at least one rival. Separates 1 of 1 rivals on the result their predictions give. A paper already fetched for this hypothesis bears on it.

05The contest

What it is competing with

Every other explanation the engine wrote for the same gap, and the observation that would separate the two.

This explanation predicts

At identical introduced-cell number, correctly distributed organizer replacement restores epithelial spatial organization, naive T-cell production and immune protection, while a concentrated depot fails. The distributed set also preserves nonimmune functional domains and improves survival without replacing peripheral ECM. Halving the dose or deleting source patches that uniquely cover a territory destroys sufficiency. If only immune outcomes improve, the proposed set is insufficient for Q0. If peripheral ligand replacement remains necessary after organizer coverage is restored, Replacing selected cell-facing matrix signals is enough to preserve function and extend life gains support over this candidate.

Rival 01 of 01
Replacing selected cell-facing matrix signals is enough to preserve function and extend life
Not yet published.
What would separate them
Replacing selected cell-facing matrix signals is enough to preserve function and extend life predicts: In an aged-animal factorial comparison, the complete acellular set preserves every prespecified functional domain and improves death-inclusive survival relative to both standard care and matched intensified nonreplacement care, despite persistence of aged host-cell genomes and no deliberate cellular replacement. Subtracting any nominated compartment or halving surface coverage loses eligibility. Thymic organizer replacement alone, as proposed by this hypothesis, improves thymic measures but fails at least one nonimmune domain. A feasible nonreplacement treatment producing equivalent durable benefit would refute replacement necessity even if ligand presentation remains causal.

06The import

Where the idea comes from

The hypothesis borrows a result from another field. This is what it borrows, and from where.

Developmental morphogenesis and pattern formation: Wolpert's positional-information threshold model, operationalized through a diffusion-decay source field. For j in {FGF7, FGF10}, use ∂c_j/∂t = D_j∇²c_j − k_jc_j + Σ_i q_ijρ_i(x). Here x is anatomical position in the thymus; t is time; c_j is extracellular concentration of factor j; D_j is its effective tissue diffusivity; ∇² describes spatial spreading; k_j is its local removal rate; i indexes a replacement patch; q_ij is secretion of factor j per cell in patch i; and ρ_i(x) is the spatial density of introduced mesenchymal cells. The range λ_j = sqrt(D_j/k_j) determines permissible source spacing. θ_j,low and θ_j,high are empirically calibrated concentration bounds for retained epithelial function, not assumed universal constants. Select patch positions so retained epithelial territories satisfy these bounds with N = Σ_i∫ρ_i(x)dV = 0.10N_M0, where N_M0 is baseline intrathymic mesenchymal-cell count and dV is anatomical volume. The candidate predicts that this coverage is attainable at10%but not5%; those claims must be tested with independently measured parameters. Source: [Positional information and the spatial pattern of cellular differentiation](https://pubmed.ncbi.nlm.nih.gov/4390734/). Applying this developmental selection law to aged thymic replacement is the proposed transfer.

07The bench

What testing it would take

The engine's own read on whether this is testable with methods that already exist.

Thymic stromal manipulation and regeneration can be studied in organotypic systems and aged mice. A primary study supports the regenerative potential of mesenchymal thymic niche cells: [Mesenchymal thymic niche cells enable regeneration of the adult thymus and T cell immunity](https://www.nature.com/articles/s41587-025-02864-w). It does not establish the proposed dose, spatial law, replacement necessity or lifespan sufficiency. Experiments must distinguish replacement of host mesenchyme from simple addition of cells and compare against matched soluble-factor and other feasible nonreplacement interventions.

08The provenance

What stands behind it

Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.

6 quantitative figures appear below and the hypothesis cites no study for any of them. They are the engine's own, and the marks in the text say which.

CitationsCites nothingFigures6 of 6 uncarriedPredictionWould tell it apart from at least one rivalTo refuteA paper already fetched for this hypothesis bears on it

What it would take to refute it. 6 paper(s) already retrieved for this hypothesis carry its prediction’s terms. Reading them comes before running anything. Already retrieved: Progress and challenges in the development of advanced pancreatic cancer organoids.; Early Embryonic Development in Agriculturally Important Species.; Human milk: insights on cell composition, organoids and emerging applications..

6 papers retrieved around this hypothesis

Acupotomy Activates PI3K/Akt Signaling Pathway Mediated by FGF7,10/KDR Axis to Regulate Apoptosis.PMID 41527667 · full_text · 60279 characters stored
Enhanced application potential of alveolar organoids through epithelial and niche cell interactions.PMID 40394147 · full_text · 56283 characters stored
Progress and challenges in the development of advanced pancreatic cancer organoids.PMID 42067869 · full_text · 132824 characters stored
Early Embryonic Development in Agriculturally Important Species.PMID 38997994 · full_text · 134241 characters stored
Genetic and Epigenetic Regulation of Cardiac Development: An Integrative View from Embryo to Human Pluripotent Stem Cell Models.PMID 42587726 · full_text · 114963 characters stored
Human milk: insights on cell composition, organoids and emerging applications.PMID 41038976 · full_text · 97555 characters stored

0 citation handles extracted; 1 Europe PMC search run; 8 records examined; 6 sources stored for enrichment, 6 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.

This is a proposed explanation, not a finding. It was written by the Omega Point engine from the literature it was given, it has not been tested, and no experiment here has been run. The numbers, methods and citations in it are model-generated and unverified. Its name was written by the Protocol Clarifier; everything else on this page is the engine's own text, carried whole.